Shares of CHF Solutions Inc (NASDAQ:CHFS) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $3.15 for the company and are predicting that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also given CHF Solutions an industry rank of 83 out of 255 based on the ratings given to its competitors.
CHFS has been the subject of several recent research reports. Dawson James initiated coverage on CHF Solutions in a report on Tuesday, August 28th. They set a “buy” rating and a $3.30 price target for the company. Zacks Investment Research upgraded CHF Solutions from a “sell” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Tuesday, July 24th. Finally, ValuEngine upgraded CHF Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd.
CHF Solutions (NASDAQ:CHFS) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.01). CHF Solutions had a negative return on equity of 166.88% and a negative net margin of 471.94%. The company had revenue of $1.10 million for the quarter. On average, research analysts expect that CHF Solutions will post -2.9 EPS for the current year.
A hedge fund recently bought a new stake in CHF Solutions stock. Perkins Capital Management Inc. acquired a new position in CHF Solutions Inc (NASDAQ:CHFS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,962 shares of the company’s stock, valued at approximately $108,000. Perkins Capital Management Inc. owned approximately 0.88% of CHF Solutions as of its most recent filing with the Securities and Exchange Commission (SEC). 20.58% of the stock is owned by institutional investors and hedge funds.
About CHF Solutions
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.